Abstract
Purpose
To report the efficacy and safety of intravitreal ranibizumab monotherapy in patients with age-related macular degeneration with a predominantly hemorrhagic lesion.
Methods
Nineteen eyes of 19 patients with submacular hemorrhage involving the fovea were treated with intravitreal ranibizumab (0.5 mg/0.05 ml) injections as needed. All patients completed at least 4 months of follow-up. Ophthalmologic examinations, fluorescence angiographic evaluations, optical coherence tomography (OCT) examination, and hemorrhage size were analyzed before the injections, and at 1,2,4,6, and 12 months follow-up.
Results
The average VA and mean central retinal thickness (CRT) before ranibizumab treatment were 0.62 ± 0.39 log MAR and 335.76 ± 111.22 μ m, respectively. Additionally, the VA and CRT four months after the initial injections were 0.54± 0.43 log MAR and 241.42 ± 107.55 μ m, respectively. The mean size of the hemorrhage was significantly reduced from 2.87 ± 2.44 DA (disk areas) at baseline to 0.9 ± 1.28 DA at four month follow up.
References
1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116:57–65.
2. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996; 16:183–9.
3. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990; 109:33–7.
4. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol. 1996; 122:486–93.
5. Sanders D, Peyman GA, Fishman G, et al. The toxicity of intravitreal whole blood and hemoglobin. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975; 197:255–67.
6. Toth CA, Morse LS, Hjelmeland LM, Landers MB 3rd. Fibrin di-rects early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991; 109:723–9.
7. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982; 94:762–73.
8. Hewitt AT, Adler R. The retinal pigment epithelium and interphotoreceptor matrix: structure and specialized functions. Ryan SJ, editor. Retina. St. Louise: CV Mosby;1994. 1:p. 58–71.
9. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999; 117:1329–45.
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–31.
11. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432–44.
12. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol. 1994; 118:559–68.
13. Lim JI, Drews-Botsch C, Sternberg P Jr, et al. Submacular hemorrhage removal. Ophthalmology. 1995; 102:1393–9.
14. Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol. 1995; 113:62–9.
15. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999; 106:1900–6. discussion 1906–7.
16. Lincoff H, Kreissig I. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration. Retina. 2001; 21:191.
17. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye. 2008; 22:82–6.
18. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol. 2007; 144:886–92.
19. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143:566–83.
20. Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006; 17:257–66.
21. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009; 247:1–11.
22. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997; 81:154–62.
23. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006; 19:361–72.
24. Sacu S, Stifter E, Vécsei-Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye. 2009; 23:1404–10.
25. Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008; 86:490–4.
26. Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999; 213:97–102.
27. Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004; 111:1993–2006.
28. Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. Clin Ophthalmol. 2010; 4:67–72.
29. Rosa RH Jr, Davis JL, Eifrig CW. Clinicopathologic reports, case reports, and small case series: clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 2002; 120:502–8.
30. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006; 141:456–62.
31. Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004; 88:809–15.
32. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol. 2010; 150:674–82.
33. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002; 133:639–48.
Table 1.
Characteristics | Value |
---|---|
Number of eyes (patients) | 19 (19) |
Age (mean ± SD*, yr) | 67.63 ± 11.45 |
Sex (M:F) | 13:6 |
Symptom duration (mean ± SD, day) | 37.58 ± 33.67 |
Number of injection (mean ± SD) | 3.53 ± 0.7 |
Baseline mean BCVA (mean ± SD, log MAR†) | 0.62 ± 0.39 |
Baseline mean central foveal thickness (mean ± SD, μ m) | 335.74 ± 111.22 |
Baseline mean lesion area (mean ± SD, DA‡) | 4.12 ± 3.18 |
Baseline mean hemorrhage area (mean ± SD, DA) | 2.87 ± 2.44 |
Mean time for the hemorrhage clear (mon [range]) | 4.1 (3–8) |
Table 2.
Pt No | Age (yr) | Sex | Follow-up months | BCVA* (log MAR†) | Baseline Lesion area (DA§) | Total area of hemorrhage (DA) | CMT‡ (μ m) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Month 1 | Month 2 | Month 4 | Baseline | Month 1 | Month 2 | Month 4 | ||||||
1 | 76 | F | 13 | 1.3 | 1.3 | 0.8 | 0.9 | 10.4 | 8.6 | 450 | 271 | 221 | 312 |
2 | 54 | M | 12 | 0.4 | 0.4 | 0.3 | 1.1 | 6.6 | 5.9 | 318 | 360 | 230 | 266 |
3 | 67 | M | 12 | 0.3 | 0.2 | 0.2 | 0.3 | 1.3 | 0.7 | 287 | 328 | 291 | 245 |
4 | 76 | M | 14 | 0.3 | 0.3 | 0.2 | 0.3 | 1.4 | 1.2 | 288 | 205 | 189 | 170 |
5 | 67 | F | 6 | 0.3 | 0.2 | 0.1 | 0.2 | 1.5 | 0.8 | 251 | 317 | 267 | 231 |
6 | 52 | M | 4 | 0.4 | 0.3 | 0.2 | 0.3 | 1.5 | 0.8 | 282 | 189 | 186 | 210 |
7 | 90 | F | 4 | 0.3 | 0.2 | 0.3 | 0.3 | 3.4 | 2.6 | 225 | 226 | 169 | 154 |
8 | 60 | M | 6 | 0.6 | 0.4 | 0.3 | 0.9 | 3.0 | 2.1 | 333 | 278 | 162 | 210 |
9 | 57 | M | 12 | 0.5 | 0.5 | 0.2 | 0.1 | 2.5 | 1.9 | 388 | 227 | 170 | 184 |
10 | 73 | F | 4 | 0.4 | 0.3 | 0.2 | 0.2 | 2.6 | 2.0 | 401 | 213 | 204 | 165 |
11 | 57 | F | 4 | 0.5 | 0.4 | 0.2 | 0.2 | 2.2 | 1.5 | 326 | 324 | 269 | 185 |
12 | 66 | M | 12 | 0.4 | 0.4 | 0.2 | 0.2 | 5.7 | 2.1 | 271 | 280 | 247 | 173 |
13 | 57 | M | 13 | 0.3 | 0.2 | 0.1 | 0.2 | 2.0 | 0.9 | 186 | 185 | 166 | 159 |
14 | 91 | M | 16 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 0.8 | 214 | 208 | 215 | 174 |
15 | 75 | M | 12 | 0.5 | 0.4 | 0.2 | 0.2 | 5.1 | 4.0 | 460 | 214 | 227 | 316 |
16 | 50 | M | 12 | 1.1 | 0.9 | 0.9 | 1.1 | 11.0 | 8.4 | 670 | 507 | 439 | 620 |
17 | 71 | M | 6 | 0.5 | 0.4 | 0.3 | 0.5 | 9.8 | 4.3 | 407 | 294 | 298 | 332 |
18 | 53 | M | 4 | 0.8 | 0.8 | 0.5 | 0.6 | 4.2 | 4.0 | 299 | 244 | 230 | 225 |
19 | 73 | F | 6 | 1.4 | 1.3 | 1.3 | 1.3 | 2.8 | 1.9 | 323 | 287 | 250 | 230 |